SEC Comment Letter 0000000000-24-004170 to TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
TEVA PHARMACEUTICAL INDUSTRIES LTD
Date: April 17, 2024 · CIK: 0000818686 · Accession: 0000000000-24-004170
AI Filing Summary & Sentiment
File numbers found in text: 001-16174
Letter
United States securities and exchange commission logo April 17, 2024 Eli Kalif Executive Vice President, Chief Financial Officer TEVA PHARMACEUTICAL INDUSTRIES LTD 124 Dvora HaNevi'a St. Tel Aviv, Israel 6944020 Re:TEVA PHARMACEUTICAL INDUSTRIES LTD Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 12, 2024 File No. 001-16174 Dear Eli Kalif: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
April 17, 2024
Eli Kalif
Executive Vice President, Chief Financial Officer
TEVA PHARMACEUTICAL INDUSTRIES LTD
124 Dvora HaNevi'a St.
Tel Aviv, Israel 6944020
Re:TEVA PHARMACEUTICAL INDUSTRIES LTD
Form 10-K for the Fiscal Year Ended December 31, 2023
Filed February 12, 2024
File No. 001-16174
Dear Eli Kalif:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences